Deloxolone
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Deloxolone
- Molecular weight
- 556.78
- Structure (SMILES)
- CC1(C)[C@@H](OC(=O)CCC(=O)O)CC[C@]2(C)C3=CC[C@@H]4[C@@H]5C[C@@](C)(C(=O)O)CC[C@]5(C)CC[C@@]4(C)[C@]3(C)CC[C@@H]12
- 3 beta hydroxyolean 9 11 en 30 oic acid hydrogen succinate
- 3.BETA.-HYDROXYOLEAN-9(11)-EN-30-OIC ACID, HYDROGEN SUCCINATE
- deloxolona
- Deloxolona
- deloxolone
- Deloxolone
- deloxolone [INN]
- deloxolone inn
- CAS registry numbers
- 68635-50-7
- ChEMBL ID
- CHEMBL2106405
- InChIKey
- VRFVGZRKFFTPCG-KYHPDETOSA-N
- PubChem compound IDs
- 205973
- FDA ingredient codes (UNII)
- I0E16819I3
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -olone
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 2
- Polar surface area
- 100.9
- Calculated partition coefficient (ALogP)
- 7.65
- Calculated partition coefficient (XLogP)
- 7.6
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 5
- Heavy atoms
- 40
- Molecular formula
- C34H52O6
- Monoisotopic mass
- 556.37638937
- Natural product
- No
Related records
Trials (49)
- A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
- A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
- A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
- A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
- A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine
- A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
- A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
- A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)
- A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)
- An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)
- An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)
- An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)
- Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
- Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)
- Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
- Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)
- Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?
- Effectiveness and B-memory Cell Response to QHPV Vaccine 9-years Post-vaccination Among HIV-infected Boys and Girls
- Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
- Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females